Home › Inflammatory Bowel Disease › Tennessee
Pag-aaral pangklinika para sa Inflammatory Bowel Disease sa Tennessee
7 pag-aaral para sa Inflammatory Bowel Disease ang naghahanap ng mga kalahok sa mga site sa Tennessee.
Mga Lungsod sa Tennessee
Opisyal na teksto ng pag-aaral (English)
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- Site 017, Kingsport
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07012395A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-003, Cordova
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07845487Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
- Xencor Investigative Site, Cordova
Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06619990A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Gastrointestinal Associates of Northeast Tennessee, Johnson City
Nagre-recruitPhase 2
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06226883A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Cordova
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Mar 12, 2026 · NCT07113522A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
- The Vanderbilt Clinic, Nashville
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 24, 2025 · NCT06699121Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
- Vanderbilt University, Nashville
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update May 8, 2025 · NCT06750731Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.